Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19108
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPetrovski, Slavé-
dc.contributor.authorTodd, Jamie L-
dc.contributor.authorDurheim, Michael T-
dc.contributor.authorWang, Quanli-
dc.contributor.authorChien, Jason W-
dc.contributor.authorKelly, Fran L-
dc.contributor.authorFrankel, Courtney-
dc.contributor.authorMebane, Caroline M-
dc.contributor.authorRen, Zhong-
dc.contributor.authorBridgers, Joshua-
dc.contributor.authorUrban, Thomas J-
dc.contributor.authorMalone, Colin D-
dc.contributor.authorFinlen Copeland, Ashley-
dc.contributor.authorBrinkley, Christie-
dc.contributor.authorAllen, Andrew S-
dc.contributor.authorO'Riordan, Thomas-
dc.contributor.authorMcHutchison, John G-
dc.contributor.authorPalmer, Scott M-
dc.contributor.authorGoldstein, David B-
dc.date.accessioned2018-09-13T00:21:03Z-
dc.date.available2018-09-13T00:21:03Z-
dc.date.issued2017-07-01-
dc.identifier.citationAmerican Journal of Respiratory and Critical Care Medicine 2017; 196(1): 82-93-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19108-
dc.description.abstractIdiopathic pulmonary fibrosis (IPF) is an increasingly recognized, often fatal lung disease of unknown etiology. The aim of this study was to use whole-exome sequencing to improve understanding of the genetic architecture of pulmonary fibrosis. We performed a case-control exome-wide collapsing analysis including 262 unrelated individuals with pulmonary fibrosis clinically classified as IPF according to American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines (81.3%), usual interstitial pneumonia secondary to autoimmune conditions (11.5%), or fibrosing nonspecific interstitial pneumonia (7.2%). The majority (87%) of case subjects reported no family history of pulmonary fibrosis. We searched 18,668 protein-coding genes for an excess of rare deleterious genetic variation using whole-exome sequence data from 262 case subjects with pulmonary fibrosis and 4,141 control subjects drawn from among a set of individuals of European ancestry. Comparing genetic variation across 18,668 protein-coding genes, we found a study-wide significant (P < 4.5 × 10-7) case enrichment of qualifying variants in TERT, RTEL1, and PARN. A model qualifying ultrarare, deleterious, nonsynonymous variants implicated TERT and RTEL1, and a model specifically qualifying loss-of-function variants implicated RTEL1 and PARN. A subanalysis of 186 case subjects with sporadic IPF confirmed TERT, RTEL1, and PARN as study-wide significant contributors to sporadic IPF. Collectively, 11.3% of case subjects with sporadic IPF carried a qualifying variant in one of these three genes compared with the 0.3% carrier rate observed among control subjects (odds ratio, 47.7; 95% confidence interval, 21.5-111.6; P = 5.5 × 10-22). We identified TERT, RTEL1, and PARN-three telomere-related genes previously implicated in familial pulmonary fibrosis-as significant contributors to sporadic IPF. These results support the idea that telomere dysfunction is involved in IPF pathogenesis.-
dc.language.isoeng-
dc.subjectcollapsing analysis-
dc.subjectexome sequencing-
dc.subjectgenetics-
dc.subjectinterstitial lung disease-
dc.subjectpulmonary fibrosis-
dc.titleAn Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis.-
dc.typeJournal Article-
dc.identifier.journaltitleAmerican Journal of Respiratory and Critical Care Medicine-
dc.identifier.affiliationGilead Sciences, Foster City, Californiaen
dc.identifier.affiliationDuke Clinical Research Institute, Durham, North Carolinaen
dc.identifier.affiliationDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolinaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationInstitute for Genomic Medicine, Columbia University Medical Center, New York, New Yorken
dc.identifier.affiliationDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolinaen
dc.identifier.affiliationDivision of Pharmacotherapy and Experimental Therapeutics, Center for Pharmacogenomics and Individualized Therapy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolinaen
dc.identifier.affiliationInstitute for Genomic Medicine, Columbia University Medical Center, New York, New York, USAen
dc.identifier.affiliationDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia-
dc.identifier.doi10.1164/rccm.201610-2088OC-
dc.identifier.orcid0000-0002-1527-961X-
dc.identifier.orcid0000-0002-4186-5698-
dc.identifier.orcid0000-0003-4695-2923-
dc.identifier.orcid0000-0002-7232-2143-
dc.identifier.pubmedid28099038-
dc.type.austinJournal Article-
dc.type.austinResearch Support, N.I.H., Extramural-
dc.type.austinResearch Support, Non-U.S. Gov't-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Feb 6, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.